Clinical Trial Update: A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing aflibercept plus docetaxel versus placebo plus docetaxel in second-line locally advanced or metastatic non-small cell lung cancer has co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Aflibercept (Aflibercept)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Sanofi | Conditions: Carcinoma, Non Small Cell Lung | Phase 3 | Status: COMPLETED | Results posted: 2013-01-01